Abbott Laboratories (NYSE:ABT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Abbott Laboratories, with 20 buy ratings, three strong-buy ratings and four holds among 27 brokerages. The average 12-month price target is $119.50.
• Abbott reported quarterly earnings of $1.31 per share, exceeding the $1.28 consensus estimate, while revenue reached $12.59 billion and increased 13% year over year.
• The company paid a quarterly dividend of $0.63 per share, equivalent to an annualized $2.52 dividend and a 2.3% yield; institutional investors and hedge funds own 75.18% of the stock.

Shares of Abbott Laboratories (NYSE:ABT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-seven brokerages that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $119.50.

Several equities research analysts recently issued reports on ABT shares. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a report on Wednesday, May 27th. Royal Bank Of Canada restated an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Piper Sandler reaffirmed an "overweight" rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. upped their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Finally, UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $108.29 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market capitalization of $187.38 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The stock has a fifty day moving average of $104.43 and a 200-day moving average of $100.12.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories's revenue was up 13.0% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source